U.S. Markets open in 6 hrs 26 mins

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)

LUGANO, Switzerland and SAN DIEGO, Jan. 11, 2018 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to pracinostat, an investigational drug candidate currently in a Phase 3 study in combination with azacitidine for the treatment of acute myeloid leukemia (AML) in adult patients unfit to induction chemotherapy.

The orphan drug designation is based on the scarcity of treatments for patients suffering from AML and on positive Phase 2 study results (see below) that were presented at the American Society of Hematology (ASH) Annual Meeting, in December 2016.

The EMA orphan drug designation is a status assigned to a medicine intended for use against a rare condition in the European Union (prevalence of the condition in the European Union must not be more than 5 in 10,000). The designation allows pharmaceutical companies to benefit from incentives offered by the EU to develop a medicine for the treatment, prevention or diagnosis of a disease that is life threatening or a chronically debilitating rare disease. These include 10 years of market exclusivity once approved, alongside a range of other regulatory advantages.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "Helsinn is pleased with the decision of the EMA to grant orphan drug designation to pracinostat. This decision encourages us to continuously dedicate significant resources to accelerate our clinical trial program, with a goal of helping patients who are fighting rare and difficult-to-treat diseases, such as AML and, at present, have very few treatment options. Following the positive Phase 2 clinical trials of pracinostat for patients with AML, Helsinn has recently initiated the Phase 3 program."

"This designation from the EMA recognizes the potential that pracinostat holds in addressing a significant unmet need for those suffering with AML," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "This represents another important milestone in the global development strategy for pracinostat."

1st patient randomized in Phase 3 trial:

In August of 2017, Helsinn and MEI Pharma announced that the first patient has been dosed in the pivotal Phase 3 study of the investigational agent pracinostat in combination with Azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who are unfit to receive intensive induction chemotherapy. The primary endpoint of the study is overall survival. Secondary endpoints include, among others, morphologic complete remission (CR) rate, cytogenetic complete remission and complete remission without minimal residual disease.

Phase 2 study results for pracinostat for the treatment of AML:

Results from a Phase 2 open-label, single-arm, multicenter study of pracinostat and azacitidine in 50 patients aged ≥ 65 years with newly diagnosed AML not eligible for induction chemotherapy showed a median overall survival of 19.1 (95%CI: 10.0-26.5) months, one-year survival of 62% and a CR rate of 42%. These results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2016.

About AML
AML is the most common acute leukemia affecting adults, and its incidence is expected to continue to increase as the population ages. The American Cancer Society estimates about 21,380 new cases and 10,590 deaths from AML in the U.S. for 2017; the average age of a patient with AML is about 67 years. According to the Surveillance of Rare Cancers in Europe project, the incidence of AML in Europe is 3.7 per 100,000. There are currently no drugs approved in the U.S. to treat AML in patients who are unfit for intensive induction chemotherapy, though hypomethylating agents are recommended by the National Comprehensive Cancer Network (NCCN) guidelines. In the EU, Azacitidine is approved for the treatment of adult patients who are not eligible for hematopoietic stem cell transplant (HSCT) with AML with >30% marrow blasts according to the World Health Organization (WHO) classification, and decitabine is approved the treatment of adult patients with newly diagnosed de novo or secondary AML, according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

About Pracinostat
Pracinostat is an oral histone deacetylase (HDAC) inhibitor that is in late-stage clinical development. The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for pracinostat in combination with Azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. In August 2016, Helsinn and MEI Pharma entered into an exclusive license, development and commercialization agreement for pracinostat in AML and other potential indications. Under the terms of the agreement, Helsinn is granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. Pracinostat is under clinical investigation and has not been approved by any health authority worldwide.

About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
For more information, please visit www.helsinn.com.

About MEI Pharma
MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes pracinostat, a late-stage oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. MEI Pharma's clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase Ib study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or follicular lymphoma, and voruciclib, an oral, selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer. For more information, please visit www.meipharma.com.

Helsinn Group and MEI Pharma Forward-Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

 

Cision

View original content:http://www.prnewswire.com/news-releases/helsinn-group-and-mei-pharma-announce-that-pracinostat-has-received-orphan-drug-designation-from-the-european-medicines-agency-for-the-treatment-of-acute-myeloid-leukemia-aml-300581189.html

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It
    World
    Fortune

    China Will Open the World's Longest Sea Bridge This Week. A Lot of People Are Unhappy About It

    Later this week, the long-awaited 34-mile sea bridge connecting mainland China to Hong Kong and Macau will finally open. In a ceremony on Tuesday that Chinese president Xi Jinping will reportedly attend, the bridge will officially open. Some critics see the Hong Kong-Zhuhai-Macau Bridge as an attempt by mainland China to tighten its grip on Hong Kong, which is an autonomous region.

  • Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson
    News
    MarketWatch

    Watch out for ‘dead cat bounce’ in stocks because there’s more pain ahead: Morgan Stanley’s Wilson

    October is living up to its infamous reputation as a volatile month for stocks with major indexes down sharply and there is likely more pain ahead for investors, according to one prominent Wall Street analyst. The recent rebound “was a dead cat bounce,” said Michael Wilson, an equity strategist at Morgan Stanley, in a report. After eking out gains last week, the S&P 500 (SPX) is trading below the 200 DMA of 2,768 Monday as stocks struggle for direction with third-quarter earnings cycle picking up pace.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • AMD's Q3 Earnings to Benefit from Strong Demand for GPUs
    Business
    Zacks

    AMD's Q3 Earnings to Benefit from Strong Demand for GPUs

    Advanced Micro Devices AMD is set to report third-quarter 2018 results on Oct 24.The company is expected to gain from robust demand of graphic processor units (GPUs), which are now profusely used in industries like gaming, automotive and blockchain.Increasing

  • Global banks curb China travel after UBS banker stopped from leaving
    Business
    Reuters

    Global banks curb China travel after UBS banker stopped from leaving

    Global banks including Citigroup and Standard Chartered have asked their private banking staff to postpone or reconsider travel to China after authorities there prevented a UBS banker from leaving the country, sources said. BNP Paribas and JPMorgan have also asked their private banking employees to reconsider their China travel plans after the authorities' action against the UBS banker, two people familiar with the matter said. Swiss private bank Julius Baer, which manages assets worth $390 billion globally, has asked staff to be cautious about China travel plans, a separate person familiar with the matter told Reuters.

  • Finance
    American City Business Journals

    Microsoft's typical worker makes $168K a year — how that compares with Facebook, Google, PayPal, Box, Salesforce, Intel and other big Bay Area tech employers

    Microsoft Corp. is the latest major Silicon Valley tech employer to reveal just how much its typical employee earns — and how that compares with its top executive. The software giant's median employee pay — almost $168,000 — is high, even by Silicon

  • Why AMD Stock Fell 11% on October 19
    Finance
    Market Realist

    Why AMD Stock Fell 11% on October 19

    Semiconductor (SMH) stock Advanced Micro Devices (AMD) fell 11.1% on October 19 to close trading at $23.66. New Street Research analyst Pierre Ferragu has a 12-month price target of $18 for AMD. Ferragu stated, “AMD’s stock price reflects a scenario we don’t believe possible.

  • Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today
    Business
    Motley Fool

    Why Pot Stocks Canopy Growth, Cronos Group, and Tilray Are Cratering Today

    Canadian pot stocks are getting hit hard across the board today. As of 1:21 p.m. EDT, for example, shares of Canopy Growth Corporation (NYSE: CGC) and Cronos Group (NASDAQ: CRON) were both down by 11.2%, whereas Tilray's(NASDAQ: TLRY) stock had fallen by 14.4%. Canopy, Cronos, and Tilray all seem to be succumbing to a so-called "sell the news" event.

  • Former General Electric vice chair on the company's futur...
    Business
    CNBC Videos

    Former General Electric vice chair on the company's futur...

    Beth Comstock, Nike board member and former vice chair of General Electric, weighs in on the future of General Electric under new CEO Larry Culp.

  • 3 Dividend Stocks That Pay You More Than Coca-Cola Does
    Business
    Motley Fool

    3 Dividend Stocks That Pay You More Than Coca-Cola Does

    With a better than 50-year history of paying dividends, Coca-Cola (NYSE: KO) is seen as an icon of stable, strong, secure payouts. Although Coke and its dividend are not in trouble, there are better investments to be found. Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D), AbbVie (NYSE: ABBV), and MGM Growth Properties (NYSE: MGP).

  • Can AMD Stock Go on a Bull Run Once Again?
    Business
    Motley Fool

    Can AMD Stock Go on a Bull Run Once Again?

    Advanced Micro Devices (NASDAQ: AMD) shares have fallen off a cliff over the past month, as investors are probably concerned about whether it can sustain its rally in the face of a fading tailwind and rising competition. The chipmaker has minted a lot of money thanks to cryptocurrency mining, but that catalyst is fizzling out and rival NVIDIA (NASDAQ: NVDA) has launched a new generation of graphics chips to reclaim its lost market share. AMD blames weak GPU sales to the cryptocurrency market for this slowdown, but recent developments indicate that it could easily surpass the low-balled guidance.

  • Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business
    Business
    Motley Fool

    Meet What Could Be Advanced Micro Devices' Next Billion-Dollar Business

    Advanced Micro Devices (NASDAQ: AMD) CEO Lisa Su said earlier this year that the company plans to achieve "mid-single-digit server unit share" by the end of 2018. The chipmaker's server chip market share crossed 1% at the end of the second quarter. Mercury Research estimates that AMD now commands 1.3% of the server market as compared to just 0.5% earlier.

  • 5 Popular Marijuana Stocks I Wouldn't Buy With Free Money
    Business
    Motley Fool

    5 Popular Marijuana Stocks I Wouldn't Buy With Free Money

    Last week on Oct. 17, Canada lifted the curtain on nine decades of prohibition and legalized recreational marijuana for adults. Given the notable surge in pot stocks since the beginning of 2016, it's pretty evident that Wall Street and investors expect the industry to be a resounding success. With that being said, there are a handful of marijuana stocks -- some quite popular -- that I simply wouldn't buy, even if I were given free money to do so.

  • Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?
    Business
    Motley Fool

    Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?

    Maybe Wall Street should be called "Weed Street." Big Canadian marijuana grower Canopy Growth listed its stock on the New York Stock Exchange (NYSE) earlier this year. Aurora Cannabis (NASDAQOTH: ACBFF) begins trading on the NYSE on Tuesday, Oct. 23. Aphria (NASDAQOTH: APHQF) filed last week to list its stock on the NYSE.

  • This Warren Buffett Stock Is Dirt Cheap Right Now
    Business
    Motley Fool

    This Warren Buffett Stock Is Dirt Cheap Right Now

    Warren Buffett has amassed a large portfolio of bank stocks for Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) with major holdings in Bank of America (NYSE: BAC), Wells Fargo (NYSE: WFC), and American Express (NYSE: AXP), just to name a few of the most well-known and largest investments. Synchrony is a major issuer of store-branded credit cards and also operates a rapidly growing online banking platform.

  • Investors Dumped Cannabis Stocks after Legalization Last Week
    Finance
    Market Realist

    Investors Dumped Cannabis Stocks after Legalization Last Week

    Cannabis Stocks Getting Dumped after Legalization? Cannabis sector Last week, the overall cannabis sector ended in negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) lost almost 5.4% of its value, while the Emerging Marijuana Growers

  • Aurora Cannabis prepares for NYSE debut on Oct. 23
    Finance
    Yahoo Finance Canada

    Aurora Cannabis prepares for NYSE debut on Oct. 23

    One of Canada’s largest marijuana producers is gearing up for its big debut on the New York Stock Exchange on Tuesday, Oct. 23. Edmonton-based Aurora Cannabis will be the third major Canadian cannabis company to go public in the U.S., where marijuana is still an illegal substance in most states. Aurora will be following in the steps of Tilray, which became the first U.S. marijuana IPO in July, and Canopy Growth, which debuted in the U.S. markets in May.

  • Aurora Cannabis is plunging ahead of its debut on the New York Stock Exchange
    Business
    Business Insider

    Aurora Cannabis is plunging ahead of its debut on the New York Stock Exchange

    Aurora Cannabis is set to begin trading on the New York Stock Exchange on Tuesday under the ticker ACB. Aurora Cannabis was plunging Monday, down more than 14%, one day ahead of the company's trading debut on the New York Stock Exchange. The Canadian producer, which grows cannabis for both the adult-use and medicinal market, has seen its market capitalization explode by more than 150% since August — to nearly $10 billion — as both corporate giants and investors have gotten in on the "green rush" into marijuana.

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • Business
    CNBC

    Two tech stocks to buy and one to avoid heading into busiest week of earnings

    "Amazon AMZN , Google GOOGL , Microsoft MSFT — we like and own all of these, and one of the things that all three have in common is that they're huge players in cloud computing and that space is going to continue to see accelerating growth over the next several years," Tepper told CNBC's " Trading Nation " on Friday.